DESIGN, DEVELOPMENT FORMULATION AND INVITRO DISSOLUTION STUDIES OF SUSTAINED MATRIX COATED TABLETS OF METFORMIN HYDROCHLORIDE
The main objective of the present work was to develop sustained release matrix tablets of Metformin hydrochloride using different polymers viz. Hydroxypropyl methyl cellulose (HPMC) and natural gums like Guar gum and Eudragit.
The tablets were evaluated for preformulation studies like angle of repose bulk density, compressibility index and physical characteristics like hardness, weight variation, friability and drug content. In-vitro release of drug was performed in PBS pH 7.2 for twelve hours. All the physical characters of the fabricated tablet were within acceptable limits. The results of in vitro data of formulation F1 containing HPMC K4M as Matrix carrier and MCC as a diluent show prolonged release. But the release was slightly faster when compared to innovator. The in vitro data of formulation F2, containing HPMC K15M as matrix carrier has shown prolonged release but at slightly faster rate when compared to innovator. Formulation F3, containing Eudragit RLPO as matrix carrier, has shown prolonged release with 10% faster rate when compared to innovator.Â F4 containing guar gum as a matrix carrier has shown prolonged release which was slightly slower when compared to innovator. From the results above it could be understood that, HPMC K4M & guar gum swell in the media and the drug entangled in its matrix is gradually leached by the media traveling the tortuous and viscous pathF8 formulation was found to be close to that of innovator. Hence the â€œnâ€ value was found to be 0.91 it shows that drug release follows super case 2 transports. It follows zero order release.
Key words: Metformin hydrochloride, Hydroxypropyl methyl cellulose, Guar gum and Eudragit.
Colocon asia lab, â€œMetformin Hcl (500mg) slow release formulation using methocell hydrophilic matricesâ€ Pharm. Tech 2004;27(3):60-5.
Fujioka , K. Pans, M.Joyal,S. â€œGlycemic Contol in patient with diabetes mellitus switch from twice daily immediate release Metformin once daily extended release formulation .â€ Clinical Therapeutics 2003;2(1):529.
Satosh .J., Jonman J.H., Aliment pharmacol Ther,Dec,1996;6(3):913-18.
Rajdziuk, J â€œMetformin a review for the treatment of type-2 diabetics and glucose production in particular, 2003;49(5):730-35.
Barbieri RL., â€œMetfromin Hcl for the treatment of polycystetic ovary syndromeâ€, J nahrol. 2003;5(4):400 - 07.
Chang CT, Chen YC ,Fang JT, Haung CC. â€œMetformin associated lactic acidosis .â€ Jnahrol.2002;15(4):398-402.
Jones, KL., â€œEffect of metformin Hcl in pediatric patients with type-2 diabetics by randomized controlled trialâ€ Pharm Res 2002;(10):1690-95.
Di colo, G. Falchi, S. Zambito,Y. â€œInvitro Evaluation Of A System Controlled Per Oral Delivery Of Metformin .â€Journal Of Controlled Release 2002;4(1):119-128.
Arno, EA.Anond ,P.Bhaskar,K,Sarvanan,M.Vinod,R.et al., â€œEudragit 30 D based Metformin /Glypezide extended release tablets; Formulation and characterization of in vitro release studies .â€ Chemical & Pharmaceutical Bulletin 2002;6(3):145-9.
Gusler, â€œAliment pharmacol. Ther 2001;6(1):914-20.
Ainaoui, A., & Vergnaud, J.M., 2000. Effect of the nature of the polymer and of the process of drug release (diffusion or erosion) for oral dosage forms. Computational and Theoretical Polymer Science. (10):383-390.
Collrt, J., & Moreton, C., 2002. Modified-release peroral dosage forms. In: Aulton, M.E., (Ed). 2002. Pharmaceutics; The Science of Dosage Form Design. 2nd Edition. Churchill Livingstone: United Kingdom:289-305.
Vasudev, S.C., Chandy, T., & Sharma, C.P., 1997. Development of chitosan/polyethylene vinyl acetate co-matrix: controlled release of aspirinheparin for preventing cardiovascular thrombosis. Biomaterials. (18):375-381.
Chein YW.Novel drug delivery systems, In: chein YW, ed.Oral drug delivery and delivery systems. New York, NY: Marcel Dekker; 1992:139-196
Vyas SP, Khar. Controlled drug delivery: concepts and advances In: Vyas SP, Khar, eds.controlled oral administration. Delhi, India: Vallabh Prakashan ; 2002: 155-195.
Vargas CI, Ghaly ES. Kinetic release of theophylline from hydrophilic swell able matrices. Drug Dev Ind Pharm. 1999;25:1045-1050.
Korsenmeyer RW, Peppas NA. Macromolecular and modeling aspects of swelling-.controlled systems. In: mansdorf SZ, Roseman TJ, eds . Controlled Release Delivery Systems. New York, NY; Marcel Dekker; 1983:77.
Alderman DA. A review of cellulose ethers in hydrophilic matrices for oral.Controlled-release dosage forms. Int J Pharm Tech Prod Mfr. 1984; 5:1-9.
Aulton ME, Wells TI, Pharmaceutics: The Science of Dosage Form Design. London,UK: Churchill Livingstone; 1988.
Shirwaikar, A.A., Jacob, S. and Grover, V. Formulation and evaluation of sustained release tablets using an insoluble rosin matrix system. Indian. J. Pharm. Sci., 2005; 67(1): 80-83.
Ruckmani, K., Aghul, B., Jaykar, B. and Ghosal, S. K. Sustained release of Nifedipine from eudragit matrix tablets. The Eastern Pharmacist, 1995, 455(11) 137-139.
Harris Shoaib,M., Jaweria Tazeen., Hamid A. Merchant. Evaluation of drug release kinetics from Ibuprofen matrix tablets using HPMC. Pak. J. Pharm. Sci., 2006, 19(2), 119-124.
Sameer, S,. Kranti, K.S., Chowdary, K.A., Deshpande, A.N., Kawode, R.M. and Wanjari, B.E. Design and evalution of sintered matrix tablets of Verapamil Hydrochloride. The Indian Pharmacist, 2008,46, 55-60.
Yeole, P. G., Galgatte., Babla, I. B. and Nkhat. D. Design and evaluation of xanthan gum based sustained release matrix tablets of Diclofenac Sodium. Indian J. Pharm. Sci., 2006, 68 (2): 185-189. 7. YORK, P., 2002. The design of dosage forms. In: AULTON, M.E., (ed).
Copyright (c) 2016 Mintage Journal of Pharmaceutical and Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.